Patents Represented by Attorney, Agent or Law Firm Matthew P. Vincent
-
Patent number: 5849989Abstract: The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of novel a transcriptional regulatory factor, referred to hereinafter as "Insulin Promoter Factor 1" or "Ipf1".Type: GrantFiled: October 7, 1994Date of Patent: December 15, 1998Assignee: Ontogeny, Inc.Inventor: Thomas Edlund
-
Patent number: 5847166Abstract: A method for preparing an aryl ether compound is provided in which an alcohol is reacted with an aromatic compound in the presence of a base, and a transition metal catalyst selected from the group consisting of platinum and nickel to form an aryl ether. The aromatic compound comprises an activated substituent, X, said activated substituent being a moiety such that its conjugate acid HX has a pKa of less than 5.0. The catalyst is preferably a soluble palladium complex in the presence of supporting ligands.Type: GrantFiled: October 10, 1996Date of Patent: December 8, 1998Assignee: Massachusetts Institute of TechnologyInventors: Stephen L. Buchwald, John P. Wolfe, Michael Palucki
-
Patent number: 5844079Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: December 14, 1994Date of Patent: December 1, 1998Assignee: President and Fellows of Harvard CollegeInventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
-
Patent number: 5837538Abstract: Invertebrate and vertebrate patched genes are provided, including the mouse and human patched genes, as well as methods for isolation of related genes, where the genes may be of different species or in the same family. Having the ability to regulate the expression of the patched gene, allows for the elucidation of embryonic development, cellular regulation associated with signal transduction by the patched gene, the identification of agonist and antagonist to signal transduction, identification of ligands for binding to patched, isolation of the ligands, and assaying for levels of transcription and expression of the patched gene.Type: GrantFiled: October 6, 1995Date of Patent: November 17, 1998Assignee: Trustees of Leland Stanford, Jr. UniversityInventors: Matthew P Scott, Lisa V. Goodrich, Ronald L. Johnson
-
Patent number: 5837840Abstract: The invention provides novel polypeptides which are associated with the transcription complex NF-AT, polynucleotides encoding such polypeptides, antibodies which are reactive with such polypeptides, polynucleotide hybridization probes and PCR amplification probes for detecting polynucleotides which encode such polypeptides, transgenes which encode such polypeptides, homologous targeting constructs that encode such polypeptides and/or homologously integrate in or near endogenous genes encoding such polypeptides, nonhuman transgenic animals which comprise functionally disrupted endogenous genes that normally encode such polypeptides, and transgenic nonhuman animals which comprise transgenes encoding such polypeptides.Type: GrantFiled: September 20, 1993Date of Patent: November 17, 1998Assignee: Board of Trustees of Leland Stanford Jr. UniversityInventors: Gerald R. Crabtree, Jeffrey P. Northrop
-
Patent number: 5834266Abstract: We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.Type: GrantFiled: August 18, 1994Date of Patent: November 10, 1998Assignees: President & Fellows of Harvard College, Board of Trustees of Leland Stanford Jr. UniversityInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5830462Abstract: Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta.Type: GrantFiled: June 7, 1995Date of Patent: November 3, 1998Assignees: President & Fellows of Harvard College, Board of Trustees of Leland S. Stanford, Jr. UniversityInventors: Gerald R. Crabtree, Stuart L. Schreiber, David M. Spencer, Thomas J. Wandless, Peter Belshaw
-
Patent number: 5795734Abstract: The present invention relates to the discovery of a novel EPH receptor ligand, referred to hereinafter as "Elf-1", which protein has apparently broad involvement in the formation and maintenance of ordered spatial arrangements of differentiated tissues in vertebrates, and can be used to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: May 31, 1995Date of Patent: August 18, 1998Assignee: President and Fellows of Harvard CollegeInventors: John G. Flanagan, Hwai-Jong Cheng
-
Patent number: 5789543Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.Type: GrantFiled: December 30, 1993Date of Patent: August 4, 1998Assignee: President and Fellows of Harvard CollegeInventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin
-
Patent number: 5780272Abstract: The present invention makes available methods and reagents for novel manipulation of nucleic acids. As described herein, the present invention makes use of the ability of intronic sequences, such as derived from group I, group II, or nuclear pre-mRNA introns, to mediate specific cleavage and ligation of discontinuous nucleic acid molecules. For example, novel genes and gene products can be generated by admixing nucleic acid constructs which comprise exon nucleic acid sequences flanked by intron sequences that can direct trans-splicing of the exon sequences to each other. The flanking intronic sequences can, by intermolecular complementation, form a reactive complex which promotes the transesterification reactions necessary to cause the ligation of discontinuous nucleic acid sequences to one another, and thereby generate a recombinant gene comprising the ligated exons.Type: GrantFiled: June 7, 1995Date of Patent: July 14, 1998Assignee: President and Fellows of Harvard CollegeInventor: Kevin A. Jarrell
-
Patent number: 5776902Abstract: The present invention makes available novel compounds useful for inhibiting kinases, phosphatases and SH2 domains, e.g., an interaction between a protein containing an SH2 domain and a phophotyrosine-containing polypeptide. In one embodiment, the present invention provides boronylphenyl analogs of phosphotyrosines which, in such forms as peptidomimetics, can be used to modulate signal transduction pathways in cells.Type: GrantFiled: May 31, 1995Date of Patent: July 7, 1998Assignee: Trustees of Tufts UniversityInventor: William W. Bachovchin
-
Patent number: 5744343Abstract: The present invention concerns three ubiquitin-conjugating enzymes.Type: GrantFiled: September 13, 1994Date of Patent: April 28, 1998Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Mark Rolfe, Jens W. Eckstein, Guillaume Cottarel
-
Patent number: 5726025Abstract: The present invention provides a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as cyclins. One aspect of the present invention relates to a method for identifying an inhibitor of ubiquitin-mediated proteolysis of a cell-cycle regulatory protein by (i) providing a ubiquitin-conjugating system that includes the regulatory protein and ubiquitin under conditions which promote the ubiquitination of the target protein, and (ii) measuring the level of ubiquitination of the subject protein brought about by the system in the presence and absence of a candidate agent. A decrease in the level of ubiquitin conjugation is indicative of an inhibitory activity for the candidate agent.Type: GrantFiled: April 20, 1995Date of Patent: March 10, 1998Assignee: President and Fellows of Harvard CollegeInventors: Marc W. Kirschner, Randall W. King, Jan-Michael Peters
-
Patent number: 5695950Abstract: A method of identifying compounds or molecules which alter (enhance or inhibit) stimulation of kinase activity of pre-MPF and, thus, alter (enhance or inhibit) activation of MPF and entry into mitosis. The present method thus makes it possible to identify compounds or molecules which can be administered to regulate the cell cycle; such compounds are also the subject of this invention.Type: GrantFiled: January 31, 1994Date of Patent: December 9, 1997Assignee: Cold Spring Harbor LaboratoryInventors: David H. Beach, Konstantin Galaktionov
-
Patent number: 5691147Abstract: The present invention relates to the discovery of novel proteins of mammalian origin which can associate with the human cyclin dependent kinase 4 (CDK4).Type: GrantFiled: June 2, 1994Date of Patent: November 25, 1997Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Jeno Gyuris
-
Patent number: 5688665Abstract: The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides a recombinant nucleic acid molecule which encodes the p27 protein of the subject invention, and related vectors and host vector systems. The subject invention further provides a method for producing the p27 protein of the subject invention using the host vector system. The subject invention further provides methods of determining whether an agent is capable of specifically inhibiting or enhancing the ability of p27 protein to inhibit the activation of cyclin E-Cdk2 complex. Finally, this subject invention provides different uses of the isolated protein, the recombinant nucleic acid molecule encoding the isolated protein and the agent capable of inhibiting or enchancing the ability of p27 protein to inhibit the activation of cyclin E-Cdk2 complex.Type: GrantFiled: July 15, 1994Date of Patent: November 18, 1997Assignees: Fred Hutchinson Cancer Research Center, Sloan-Kettering Institute for Cancer ResearchInventors: Joan Massague, James M. Roberts, Andrew Koff, Kornelia Polyak
-
Patent number: 5672508Abstract: The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced. More specifically, the inhibitors of the invention are chimeric proteins which include CDK-binding motifs from two or more different proteins. For example, the subject chimeric proteins can be generated from the in-frame fusion of coding sequences from two different CDK inhibitor proteins, such as may be derived from fusion of coding sequences for an INK4 protein and coding sequences for a CIP protein. Chimeric proteins of the present invention have been observed to be more potent inhibitors of cyclin/CDK complexes than were either of the portions of the chimeric protein individually.Type: GrantFiled: January 23, 1996Date of Patent: September 30, 1997Assignee: Mitotix, Inc.Inventors: Jeno Gyuris, Lou Lamphere, David Beach
-
Patent number: 5580979Abstract: The present invention makes available novel compounds represented by the general formula ##STR1## wherein Y represents a phosphate analog. Which compounds are useful for inhibiting an interaction between a protein containing an SH2 domain and a phophotyrosine-containing polypeptide.Type: GrantFiled: March 15, 1994Date of Patent: December 3, 1996Assignee: Trustees of Tufts UniversityInventor: William W. Bachovchin
-
Patent number: 5498531Abstract: The present invention makes available methods and reagents for novel manipulation of nucleic acids. As described herein, the present invention makes use of the ability of intronic sequences, such as derived from group I, group II, or nuclear pre-mRNA introns, to mediate specific cleavage and ligation of discontinuous nucleic acid molecules. For example, novel genes and gene products can be generated by admixing nucleic acid constructs which comprise exon nucleic acid sequences flanked by intron sequences that can direct trans-splicing of the exon sequences to each other. The flanking intronic sequences can, by intermolecular complementation, form a reactive complex which promotes the transesterification reactions necessary to cause the ligation of discontinuous nucleic acid sequences to one another, and thereby generate a recombinant gene comprising the ligated exons.Type: GrantFiled: September 10, 1993Date of Patent: March 12, 1996Assignee: President and Fellows of Harvard CollegeInventor: Kevin A. Jarrell
-
Patent number: 5443962Abstract: The present invention makes available assays and reagents for identifying anti-proliferative agents, such as mitotic and meiotic inhibitors, especially inhibitors of cdc25 phosphatase. The present assay provides a simple and rapid screening test which relies on scoring for positive cellular proliferation as indicative of anti-mitotic or anti-meiotic activity, and comprises contacting a candidate agent with a cell which has an impaired cell-cycle checkpoint and measuring the level of proliferation in the presence and absence of the agent. The checkpoint impairment is such that it either causes premature progression of the cell through at least a portion of a cell-cycle or inhibition of normal progression of the cell through at least a portion of a cell-cycle, but can be off-set by the action of an agent which inhibits at least one regulatory protein of the cell-cycle in a manner which counter-balances the effect of the impairment.Type: GrantFiled: June 4, 1993Date of Patent: August 22, 1995Assignee: Mitotix, Inc.Inventors: Giulio Draetta, Guillaume Cottarel, Veronique Damagnez